Tweet
Acadian Asset Management LLC reduced its position in shares of Mallinckrodt PLC (NYSE:MNK) by 87.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,174 shares of the company's stock after selling 74,843 shares during the period. Acadian Asset Management LLC's holdings in Mallinckrodt were worth $208,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of MNK. Scopia Capital Management LP raised its position in shares of Mallinckrodt by 111.2% during the 1st quarter. Scopia Capital Management LP now owns 8,626,365 shares of the company's stock valued at $124,910,000 after acquiring an additional 4,541,078 shares in the last quarter. Millennium Management LLC raised its position in shares of Mallinckrodt by 436.9% during the 1st quarter. Millennium Management LLC now owns 1,078,581 shares of the company's stock valued at $15,618,000 after acquiring an additional 877,699 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its position in shares of Mallinckrodt by 109.9% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 1,436,142 shares of the company's stock valued at $20,794,000 after acquiring an additional 751,838 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Mallinckrodt by 22.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,077,402 shares of the company's stock valued at $59,041,000 after acquiring an additional 735,529 shares in the last quarter. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Mallinckrodt during the 1st quarter valued at approximately $7,432,000. Get Mallinckrodt alerts:
Several equities research analysts recently issued reports on MNK shares. Cantor Fitzgerald set a $42.00 price target on Mallinckrodt and gave the company a "buy" rating in a research report on Monday, April 30th. Piper Jaffray Companies reissued a "buy" rating and set a $39.00 price target on shares of Mallinckrodt in a research report on Wednesday, August 8th. Morgan Stanley dropped their price target on Mallinckrodt from $27.00 to $14.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 9th. Canaccord Genuity set a $14.00 target price on Mallinckrodt and gave the stock a "hold" rating in a research report on Tuesday, May 8th. Finally, Oppenheimer reaffirmed a "hold" rating on shares of Mallinckrodt in a research report on Tuesday, May 15th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have issued a buy rating to the company's stock. The company presently has an average rating of "Hold" and an average price target of $31.53. Shares of NYSE MNK opened at $34.14 on Friday. Mallinckrodt PLC has a 1-year low of $11.65 and a 1-year high of $41.70. The company has a current ratio of 2.27, a quick ratio of 2.06 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of 4.39, a P/E/G ratio of 0.48 and a beta of 1.36.
Mallinckrodt (NYSE:MNK) last issued its earnings results on Tuesday, August 7th. The company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.48 by $0.30. Mallinckrodt had a return on equity of 10.39% and a net margin of 59.85%. The firm had revenue of $631.70 million for the quarter, compared to analyst estimates of $621.15 million. sell-side analysts anticipate that Mallinckrodt PLC will post 6.67 EPS for the current fiscal year.
About Mallinckrodt
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Further Reading: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK). Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter 